Affimed N V Quick Ratio (AFMD) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Affimed N v   (NASDAQ: AFMD)

Affimed N V 's Quick Ratio

AFMD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2024, Quick Ratio deteriorated to 0.65 a new company low.

Within Major Pharmaceutical Preparations industry 465 other companies have achieved higher Quick Ratio than Affimed N V in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 1407 to 3026.

Explain Quick Ratio?
How much Cash & cash equivalents AFMD´s has?
What are AFMD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AFMD Quick Ratio (Jun 30 2024)
Q2		 (Dec 31 2023)
Q4		 0
Q3		 0
Q2		 0
Q1
Y / Y Current Liabilities Change -38.46 % -25.23 % -60.28 % -25.23 % -60.28 %
Y / Y Cash & cash equivalent Change -73.28 % -79.75 % -80.71 % -79.75 % -80.71 %
Quick Ratio MRQ 0.65 1.49 1.49 1.49 1.49
AFMD's Total Ranking # 3026 # 1407 # 1080 # 1080 #
Seq. Current Liabilities Change -38.46 % 0 % 0 % 0 % -25.23 %
Seq. Cash & cash equivalent Change -73.28 % 0 % 0 % 0 % -79.75 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 466
Healthcare Sector # 863
Overall Market # 3026


Quick Ratio Statistics
High Average Low
5.49 2.92 0.65
(Dec 31 2022)   (Jun 30 2024)




Financial Statements
Affimed N V 's Current Liabilities $ 18 Millions Visit AFMD's Balance sheet
Affimed N V 's Cash & cash equivalent $ 12 Millions Visit AFMD's Balance sheet
Source of AFMD's Sales Visit AFMD's Sales by Geography


Cumulative Affimed N V 's Quick Ratio

AFMD's Quick Ratio for the trailling 12 Months

AFMD Quick Ratio

 (Jun 30 2024)
12 Months		 (Dec 31 2023)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth -41.62 % -48.12 % -51.07 % -33.75 % -38.02 %
Y / Y Cash & cash equivalent TTM Growth -79.66 % -80.24 % -61.15 % -40.52 % -25.49 %
Quick Ratio TTM 1.34 1.49 2.72 3.08 3.86
Total Ranking TTM # 4437 # 3983 # 3786 # 3117 #
Seq. Current Liabilities TTM Growth -9.61 % -7.78 % -25.92 % -5.45 % -19.68 %
Seq. Cash & cash equivalent TTM Growth -18.32 % -49.61 % -34.51 % -24.52 % -20.66 %

Quick ratio ranking by company, industry and sector >> Back to AFMD Financial Strength Comparisons >> Go to Compare AFMD Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in AFMD's Current Liabilities to $17.86 millions, cumulative Quick Ratio to 1.34 below the AFMD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 555 other companies have achieved higher Quick Ratio than Affimed N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 3983 to 4437.

Explain Quick Ratio?
How much Cash & cash equivalents AFMD´s has?
What are AFMD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 556
Healthcare Sector # 1116
Within the Market # 4437


trailing twelve months Quick Ratio Statistics
High Average Low
5.49 2.92 1.49
(Dec 31 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Novo Nordisk A  1.77 $ 7,586.826  Millions$ 4,274.367  Millions
Galectin Therapeutics Inc   1.75 $ 25.598  Millions$ 14.617  Millions
Evolus Inc   1.73 $ 93.671  Millions$ 54.118  Millions
Ani Pharmaceuticals Inc  1.72 $ 240.110  Millions$ 139.978  Millions
Cellectar Biosciences Inc   1.71 $ 25.869  Millions$ 15.091  Millions
Alkermes Plc   1.70 $ 876.117  Millions$ 515.549  Millions
Axsome Therapeutics Inc   1.69 $ 315.657  Millions$ 186.570  Millions
Shuttle Pharmaceuticals Holdings Inc   1.69 $ 2.339  Millions$ 1.385  Millions
Equillium Inc   1.68 $ 33.299  Millions$ 19.819  Millions
Tuhura Biosciences Inc   1.66 $ 4.909  Millions$ 2.950  Millions
Vertex Pharmaceuticals Inc  1.63 $ 5,795.500  Millions$ 3,547.200  Millions
G1 Therapeutics Inc   1.62 $ 60.730  Millions$ 37.504  Millions
Zevra Therapeutics Inc   1.62 $ 49.258  Millions$ 30.449  Millions
Gyre Therapeutics Inc   1.61 $ 25.100  Millions$ 15.574  Millions
Verrica Pharmaceuticals Inc   1.59 $ 31.930  Millions$ 20.051  Millions
Acelyrin Inc   1.55 $ 128.211  Millions$ 82.452  Millions
Amicus Therapeutics inc   1.55 $ 260.062  Millions$ 168.066  Millions
Abivax Sa  1.53 $ 161.528  Millions$ 105.279  Millions
Aptevo Therapeutics Inc   1.49 $ 8.066  Millions$ 5.419  Millions
Acadia Pharmaceuticals Inc   1.48 $ 500.942  Millions$ 337.851  Millions
Macrogenics Inc   1.45 $ 83.932  Millions$ 57.906  Millions
Nurix Therapeutics Inc   1.45 $ 116.790  Millions$ 80.779  Millions
Ainos Inc   1.40 $ 8.014  Millions$ 5.743  Millions
Spero Therapeutics Inc   1.39 $ 63.527  Millions$ 45.633  Millions
Notable Labs Ltd   1.39 $ 4.092  Millions$ 2.948  Millions
Kamada Ltd   1.38 $ 56.547  Millions$ 40.896  Millions
Protagenic Therapeutics Inc new  1.37 $ 0.925  Millions$ 0.675  Millions
Bio path Holdings inc   1.36 $ 4.006  Millions$ 2.955  Millions
Clearmind Medicine Inc  1.35 $ 5.563  Millions$ 4.131  Millions
Beone Medicines Ltd   1.34 $ 2,592.655  Millions$ 1,938.768  Millions

Date modified: 2026-09-18T15:15:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.